LTR 154: From Procedures to Judgment - Leading Through QMSR Inspections

Summary“FDA isn’t just inspecting procedures anymore. They are looking at how risk-based decisions are actually made.”In this episode of the Let’s Talk Risk Podcast, host Naveen Agarwal speaks with Michelle Lott about what early FDA 483 observations under QMSR are already revealing: a clear shift from procedural compliance to evaluating how well companies actually make risk-based decisions across their quality systems.This conversation goes beyond clauses and documentation. It explores how FDA is now looking at system effectiveness, how risk must be integrated across the full product lifecycle, and why leadership teams need to rethink how decisions are made, justified, and communicated under increasing ambiguity.Michelle brings a practical, field-level perspective on what is changing, where companies are most vulnerable, and how QA/RA teams can prepare their organizations for a more dynamic, judgment-driven inspection model.Key Points* FDA is increasingly citing deficiencies in risk management and system-level effectiveness, not just individual subsystems.* QMSR shifts inspections toward how decisions are made, not just whether procedures exist.* ISO 14971 alone is not enough—risk must extend across processes, lifecycle stages, and QMS interactions.* Post-market signals—not just complaints—are becoming critical inputs to risk management.* Leadership involvement, especially through management review, will face greater scrutiny under QMSR.Chapters00:00 – QMSR and the New FDA Inspection LensWhat early 483s reveal about how inspections are changing05:30 – Risk Management Beyond the Procedure (Clause 7.1)Why risk must connect across the full product lifecycle10:40 – What “Risk-Based Approach” Really Means (Clause 4.1.2(b))How FDA may evaluate decision-making, not just documentation17:00 – Management Review, CAPA, and Leadership AccountabilityWhy effectiveness and escalation matter more than timeliness21:30 – From Feedback to Signals (Clause 8.2.1)How post-market data and external signals feed a living risk system31:30 – What QA/RA Leaders Should Do NowHow teams can prepare for a more judgment-driven inspection modelIf you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.Suggested links:* LTR: Risk, CAPA and FDA Inspections under QMSR.* LTR: QMSR Readiness, Risk-Based Assurance and FDA Expectations.* LTR: A 90-Day Plan to Review QMSR Readiness.KeywordsQMSR, FDA inspections, ISO 13485, risk-based approach, risk management, CAPA, preventive action, post-market surveillance, safety signals, management review, quality systems, MedTech regulation, 483 observations, system effectivenessAbout Michelle LottMichelle Lott is the founder of Lean RAQA, where she provides fractional RA/QA leadership, audit prep, quality system design, and regulatory strategy for MedTech startups and small companies. With 20+ years of experience and an RAC certification, Michelle has helped hundreds of firms navigate FDA submissions and ISO compliance, bringing clarity and efficiency to even the most complex regulatory challenges.DisclaimerInformation and insights presented in this podcast are for educational purposes only. Views expressed by all speakers are their own and do not reflect those of their respective organizations.Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe